Novo Nordisk's Q4 results hinge on Ozempic and Wegovy sales as demand growth slows amid guidance cuts due to intense rivalry and compounded drug headwinds.

Novo Nordisk's Wegovy pill was prescribed more than 18,000 times in the U. in the first full week after its launch in an ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about ...

The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.

As GLP-1 pills for weight loss enter the U.S. market, some pharmaceutical companies are testing the possibility of a gene therapy to stimulate GLP-1 production, The Washington Post reported Jan. 24.

Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity ...

At a high level these drugs mimic glucagon-like peptide-1, or GLP-1, a hormone our bodies naturally produce in the gut. When ...

Because nausea and constipation are common side effects of GLP-1s (the class of drug that includes Ozempic, Wegovy and ...

The source of this renewed optimism lies in concrete figures related to the U.S. launch of the oral Wegovy variant in January 2026. Market observers believe the daily pill could be a decisive factor ...

However, not everyone is willing—or able—to indefinitely commit to GLP-1s.

Novo Nordisk A/S is rated a Buy with solid long-term prospects, and the stock appears undervalued. Learn more about NVO stock ...